Travere Therapeutics, Inc. TVTX 深 沪
等待开盘 06-26 09:30:00 美东时间
59.05
+1.360
+2.36%
华盛通- 最 高60.10
- 今 开57.85
- 成交量 251.88万股
- 最 低 54.13
- 昨 收 57.69
- 总市值 375.05万
- 52周最高 60.10
- 市盈率 静 --
- 换手率 3965.75%
- 52周最低 14.44
- 委 比 -31.43%
- 总股本 6.35万
- 历史最高 60.10
- 量 比 1.10
- 振 幅 10.35%
- 历史最低 0.90
- 每 手 1
- 风险率 9.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
Crude Oil Falls Sharply; Wells Fargo Earnings Miss Views
Dow Jones up 200 points, consumer discretionary shares rise 1.8%, Wells Fargo reports worse-than-expected earnings, Avanos Medical surges 69%.
04-15 00:30
Earnings Scheduled For February 19, 2026
Companies Reporting Before The Bell • Deere (NYSE:DE) is expected to report qua...
02-19 19:11
Earnings Outlook For Travere Therapeutics
Travere Therapeutics (NASDAQ:TVTX) will release its quarterly earnings report o...
02-19 01:01
The Insider Report: The Dip Was Bought Before the Holidays
Market Overview As I shared in last week's report, the dip buying opportunity i...
2025-11-30 23:04
单日暴涨130%+，肾病领域再成行业焦点
转自：新康界 4月30日，诺华公司宣布以17亿美元收购美股上市医药公司Regulus(NASDAQ:RGLS)，受此消息影响，Regulus的股价...
2025-06-23 19:50
2025年美股Biotech有望大涨 摩根大通首选福泰制药
华尔街金融巨头摩根大通近日发布研报称，对于2025年美股市场的生物科技公司（即Biotech）股价走势持乐观看涨立场，预计Biotech有望跑赢美股大盘，其中美股Biotech领军者之一的福泰制药（VRTX.US）在摩根大通的2025年最佳Biotech选股名单中位列榜首。在美联储开启降息的大背景下，生物科技类股票可谓是最佳受益于降息周期的股票板块，在降息周期之下资金有望从近年来股价持续暴涨且估值处于历史高位的大型科技巨头们转向一些受益于降息周期且估值自2022年以来长期低迷的生物科技股。 据了解，在摩根大通最新发布的研报中，该机构2025年最看好的生物科技公司除了位列股票名单首选位置...
2024-11-26 15:22
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock increased by 16.8% to $0....
2024-09-27 04:31
Analyst Ratings For Travere Therapeutics
Providing a diverse range of perspectives from bullish to bearish, 8 analysts h...
2024-09-07 05:00
Travere Says FDA Has Granted Full Approval To FILSPARI (Sparsentan) To Slow Kidney Function Decline In Adults With Primary IgAN Who Are At Risk Of Disease Progression
FILSPARI was granted accelerated approval in February 2023 based on the surrogate marker of proteinuria. Full approval is based on positive long-term confirmatory results from the PROTECT Study demonstrating that
2024-09-06 05:36
